Genetic variation is relatively poorly studied in the Middle East, particularly where endogamy and consanguinity are more common. Among 6K WGS in Qatar, 2 in 3 (!) was a carrier for a pathogenic mutation for an autosomal recessive condition. link.springer.com/article/10.118……

🚨 Update 🚨

Congrats, Evan! Evangelos K Oikonomou

Amazing presentation & another win. CarDS Lab

Happening now: Emily Lau, MD, MPH giving the Zipes Distinguished Young Scientist award keynote on women's cardiovascular disease! #ACC24

Original Article: Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md/4cEb6EB

Editorial: Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment nej.md/3vFF1LK

American College of Cardiology #ACC24

Presented today at #ACC24 :

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Looking forward to talking about ancestry-specific biases in tumor mutational burden with Alanna Church, MD in a few weeks! Related to our prior work here: pubmed.ncbi.nlm.nih.gov/36179682/

Here is our schedule of talks for the rest of the academic year. If you are interested in participating in the AHFTC Lecture Series, please email [email protected], introduce yourself, and explain your interest. Lectures commence at 12:30 pm Eastern over Zoom. Yale Heart Failure

📢 #CCCEnthusiasts ! 📅 Mark your calendars for our April Journal Club featuring Drs. Jason N. Katz & BalimSenman discussing the highly anticipated DanGer Shock trial results! Reserve your spot and get event details by RSVPing today!
ccc1stop.com/event-details/…

Updated preprint is now up. A bit more data and some new authors!

Thread below if you haven't seen this work yet 👊
Kathryn McGurk James Ware
medrxiv.org/content/10.110…

EHR tools can narrow the implementation gap of MRA initiation. Katherine Clark Godiksen Sarah Abou Alaiwi and Matthew Colna discuss factors to consider when designing best practice alerts for implementing #GDMT . JACC Journals Yale Cardiology
jacc.org/doi/10.1016/j.…

Ensight-AI, a company founded by a group led by Rohan Khera, has received a Breakthrough Device Designation from the U.S. FDA for a technology it developed to detect TTR amyloid cardiomyopathy - an often underdiagnosed condition. CarDS Lab Yale Cardiology

1st JC of ECLS-SHOCK by CCCEnthusiasts!
🌟Elliott Miller teaching stats & design - 🗝️ to understand trials
🌟Inclusion/Exclusion criteria=huge implications
🌟Where does this leave #ECMO in CS?
🌟Something else at play in these pts?

Carlos L. Alviar MD, FACC Jason N. Katz BalimSenman

👏Congratulations to Antonella and Renato Polimanti for leading this valuable study evaluating TTR amyloidogenic mts across different genetic ancestries in the UK biobank and their correlation with different clinical phenotypes Edward Miller, MD PhD
humgenomics.biomedcentral.com/articles/10.11…

“We have pioneered a specialized procedure, called coronary function testing, to figure out the cause of reduced blood flow to the heart in patients who don't have blockages, or blockages that have already been treated.'
Samit Shah, MD, PhD
ynhh.org/services/heart…

🎉 CCC Enthusiasts! Mark your calendars🗓for our inaugural Journal Club on March 27th, 5-6:30pm EDT. Join Dr. Divya Iyer and Elliott Miller from Yale Cardiology as they dive into the ECLS-SHOCK trial.
RSVP now and don't miss out!👇
shoutout.wix.com/so/e6OvM5umh?l…

It’s that great time of year when we find out about the next generation of MDs joining us at Brigham and Women's Hospital!

Welcome to the incredible new Brigham and Women's Medicine Residents Intern Class of 2024!

Amazing to see that 21% from URIM backgrounds! Brigham and Women’s D & I

Congratulations Renee Maria Saliby!!! so lucky to have you join the New Haven crew!

Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. bit.ly/3OvJiYD

#JACCCardioOnc #CardioOnc #Immunotherapy Amin Nassar, MD